Evidence map›Paper›PMID 29336114›Full record

ArticleCNS neuroscience & therapeutics2018

Nucleolar and spindle-associated protein 1 is a tumor grade correlated prognosis marker for glioma patients.

Tao Zhu, Pan Xie, Yuan-Feng Gao, Ma-Sha Huang, Xi Li, Wei Zhang, Hong-Hao Zhou, Zhao-Qian Liu

Abstract read
In one paragraph

Article in CNS neuroscience & therapeutics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Annexin A2: regulating glioma's fate and a potential therapeutic target.Medical oncology (Northwood, London, England) · 2025
    Article
  2. The role and therapeutic value of NUSAP1 in human cancers.Journal of translational medicine · 2025
    Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. EZH2 is a potential prognostic predictor of glioma.Journal of cellular and molecular medicine · 2021
    Article
  12. Article
  13. Article
  14. Article
  15. BioMed research international · 2020
    Article
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tao ZhuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Pan XieDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Yuan-Feng GaoDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Ma-Sha HuangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Xi LiDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Wei ZhangDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Hong-Hao ZhouDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.
Zhao-Qian LiuDepartment of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0003-0428-3928

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsDespite therapeutic advances in glioma management including surgery, radiation, and chemotherapy, the improvement of patient outcome is far from satisfactory. Nucleolar and spindle-associated protein 1 (NUSAP1) is an important functional protein during mitosis, and its abnormal expression is implicated in progression of different types of tumors. However, the role of NUSAP1 in gliomas remains unclear.

methodsNUSAP1 expression in gliomas with different grades was investigated based on GEO glioma datasets. Kaplan-Meier survival analysis was used to evaluate its prognostic significance. In vitro assays were also performed to evaluate effects of NUSAP1 on malignant phenotypes of glioma cells by silencing NUSAP1.

resultsNUSAP1 expression was correlated not only with glioma grade but also with prognosis of glioma patients. NUSAP1 depletion suppressed proliferation of U251 cells by inducing cell cycle arrest at G2/M phase and apoptosis. NUSAP1 depletion rendered U251 cells impaired migratory ability as well.

conclusionNUSAP1 is a potential prognosis marker for glioma patients and therapeutic strategies targeting NUSAP1 might hold promise in improving glioma treatment.

Indexed as

AdultApoptosisBiomarkers, TumorBrain NeoplasmsCell CycleCell Line, TumorCell MovementCell ProliferationFemaleGliomaHumansMaleMicrotubule-Associated ProteinsMiddle AgedPrognosisRNA, MessengerBiomarkers, TumorMicrotubule-Associated ProteinsNUSAP1 protein, humanRNA, Messengergene expression profileGliomaNUSAP1pathological gradeprognosis

Identifiers

PMID29336114
PMCPMC6490140

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.